Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response (CORAL)

This study has been completed.
Information provided by (Responsible Party):
Kirby Institute Identifier:
First received: October 14, 2008
Last updated: July 23, 2012
Last verified: July 2012
Results First Received: May 6, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Factorial Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: HIV Infections
Interventions: Drug: Raltegravir
Drug: Hyper-immune Bovine Colostrum
Other: raltegravir placebo
Other: Hyper-immune Bovine Colostrum placebo
Drug: raltegravir and hyper-immune bovine colostrum

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Raltegravir + Hyper-immune Bovine Colostrum Raltegravir and hyper-immune bovine colostrum
Hyper-immune Bovine Colostrum Hyper-immune bovine colostrum and Raltegravir placebo
Raltegravir Raltegravir and Hyper-immune Bovine Colostrum placebo
Placebo Raltegravir placebo and hyper-immune bovine colostrum placebo
Total Total of all reporting groups

Baseline Measures
    Raltegravir + Hyper-immune Bovine Colostrum     Hyper-immune Bovine Colostrum     Raltegravir     Placebo     Total  
Number of Participants  
[units: participants]
  19     19     18     17     73  
[units: participants]
<=18 years     0     0     0     0     0  
Between 18 and 65 years     18     18     17     16     69  
>=65 years     1     1     1     1     4  
[units: years]
Mean (Standard Deviation)
  52  (11)     56  (9)     50  (10)     55  (10)     53  (10)  
[units: participants]
Female     2     1     0     1     4  
Male     17     18     18     16     69  
Region of Enrollment  
[units: participants]
Australia     19     19     18     17     73  

  Outcome Measures

1.  Primary:   Mean Change From Baseline CD4+ Cell Count   [ Time Frame: 24 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Effect of interventions only measured in peripheral blood

  More Information